22:56 , Apr 20, 2018 |  Emerging Company Profile  |  Emerging Company Profile

Clear for Landos

Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and safety over standard-of-care therapies for inflammatory bowel disease (IBD), including moderate to severe Crohn’s disease (CD) and ulcerative colitis...
07:00 , Jun 4, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: NLR family member X1 (NLRX1)

Pulmonary disease INDICATION: Chronic obstructive pulmonary disease (COPD) Studies in mice and patient samples suggest promoting NLRX1 could help treat cigarette smoke-induced COPD. Levels of NLRX1 mRNA were lower in lung tissue samples from patients...
07:00 , Jul 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus NLR family member X1 (NLRX1) In vitro and mouse studies suggest activating NLRX1 could help treat influenza. In human cell culture, small...